PDCD1 and metastatic melanoma: This nationwide prospective interventional study investigates the safety of early discontinuation of maintenance treatment with anti-PD-1 in patients with irresectable stage III or metastatic melanoma who are treated with combination therapy of ipilimumab and nivolumab.